Literature DB >> 23610450

Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Michael Ittmann1, Jiaoti Huang, Enrico Radaelli, Philip Martin, Sabina Signoretti, Ruth Sullivan, Brian W Simons, Jerrold M Ward, Brian D Robinson, Gerald C Chu, Massimo Loda, George Thomas, Alexander Borowsky, Robert D Cardiff.   

Abstract

Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of the complex biology of prostate cancer and promises to enhance development of new approaches to prevention, detection, and treatment of this common malignancy.

Entities:  

Mesh:

Year:  2013        PMID: 23610450      PMCID: PMC3644021          DOI: 10.1158/0008-5472.CAN-12-4213

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  70 in total

1.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

Authors:  Helen B Pearson; Pedro A Perez-Mancera; Lukas E Dow; Andrew Ryan; Pierre Tennstedt; Debora Bogani; Imogen Elsum; Andy Greenfield; David A Tuveson; Ronald Simon; Patrick O Humbert
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

2.  Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

Authors:  David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu
Journal:  Cancer Cell       Date:  2011-05-27       Impact factor: 31.743

3.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.

Authors:  Pradip K Majumder; Jen Jen Yeh; Daniel J George; Phillip G Febbo; Jennifer Kum; Qi Xue; Rachel Bikoff; Hongfeng Ma; Philip W Kantoff; Todd R Golub; Massimo Loda; William R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-10       Impact factor: 11.205

4.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 5.  Prostate cancer in dogs: comparative and clinical aspects.

Authors:  Bruce E Leroy; Nicole Northrup
Journal:  Vet J       Date:  2008-09-10       Impact factor: 2.688

6.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

7.  Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.

Authors:  Victor D Acevedo; Rama D Gangula; Kevin W Freeman; Rile Li; Youngyou Zhang; Fen Wang; Gustavo E Ayala; Leif E Peterson; Michael Ittmann; David M Spencer
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

Review 8.  Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.

Authors:  Shazia Irshad; Cory Abate-Shen
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

9.  Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.

Authors:  F Yang; D W Strand; D R Rowley
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  123 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

2.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

Review 3.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

4.  Digital Microscopy, Image Analysis, and Virtual Slide Repository.

Authors:  Famke Aeffner; Hibret A Adissu; Michael C Boyle; Robert D Cardiff; Erik Hagendorn; Mark J Hoenerhoff; Robert Klopfleisch; Susan Newbigging; Dirk Schaudien; Oliver Turner; Kristin Wilson
Journal:  ILAR J       Date:  2018-12-01

Review 5.  Prostate organogenesis: tissue induction, hormonal regulation and cell type specification.

Authors:  Roxanne Toivanen; Michael M Shen
Journal:  Development       Date:  2017-04-15       Impact factor: 6.868

Review 6.  Prostate Cancer Research at the Crossroads.

Authors:  Michael M Shen; Mark A Rubin
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

7.  Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.

Authors:  Jake Higgins; Michele Brogley; Nallasivam Palanisamy; Rohit Mehra; Michael M Ittmann; Jun Z Li; Scott A Tomlins; Diane M Robins
Journal:  Horm Cancer       Date:  2015-01-29       Impact factor: 3.869

8.  PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.

Authors:  Matthew T Jefferies; Adam C Cox; Boris Y Shorning; Valerie Meniel; David Griffiths; Howard G Kynaston; Matthew J Smalley; Alan R Clarke
Journal:  J Pathol       Date:  2017-11-14       Impact factor: 7.996

9.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Celine Lefebvre; Mariano J Alvarez; Mireia Castillo-Martin; Tian Zheng; James A Eastham; Anuradha Gopalan; Kenneth J Pienta; Michael M Shen; Andrea Califano; Cory Abate-Shen
Journal:  Cancer Cell       Date:  2014-05-12       Impact factor: 31.743

10.  Pathology Principles and Practices for Analysis of Animal Models.

Authors:  Sue E Knoblaugh; Tobias M Hohl; Krista M D La Perle
Journal:  ILAR J       Date:  2018-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.